India’s Gland Pharma To Buy Cenexi For $124 mln

(CTN NEWS) – As it seeks to increase its footprint in European markets, Indian generic injectables manufacturer Gland Pharma Ltd announced on Tuesday that it would purchase privately held French pharmaceutical company Cenexi for 120 million euros ($124.3 million).

With three manufacturing facilities in France and one in Belgium, Cenexi is a contract development and manufacturing business that creates sterile and injectable pharmaceutical products.

-U.S. stocks gain as risk-off tone ebbs.

-Gland Pharma to buy France's Cenexi Group

-BCCI's conflict of interest notice to Binny

-Biocon Biologics completes Viatris unit buyout

-SEBI caps debt investments in active funds

Get the day's top news: https://t.co/V3sVSogtIg pic.twitter.com/HlBnq7BUHF

— BQ Prime (@bqprime) November 29, 2022

Cenexi was separated from Roche Holding in 2004.

With exports to international markets, Europe generates most of Cenexi’s revenue. Its revenue decreased from 195.3 million euros in 2020 to 184.1 million euros in 2021.

The US, Europe, Canada, and Australia are the main markets for Gland Pharma.

72% of the second quarter’s income came from the countries.

The business claims that the acquisition has an enterprise value of 230 million euros, including debt, and will be financed with internal funds.

The statement comes hours after Bloomberg News reported that Shanghai Fosun Pharmaceutical Group Co Ltd.

The parent company of Gland Pharma in China was considering selling the business, which caused Gland’s shares to rise 7.6%.

RELATED CTN NEWS:

Black Friday Online Sales Sets A New Record Of $9 Billion

Bitfront A Crypto Exchange To Shut Down